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Estrogen receptors are hormone-inducible transcription factors requiring coactivators such as members of
the SRC/p160 family to modulate the transcription of their target genes.This perspective will examine the
interplay between estrogen receptors and their coactivators in vasoprotection during vascular wall remodeling.
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Introduction
The vasoprotective effects of estrogen are well
recognized.The incidence of cardiovascular disease
among premenopausal is significantly less than that
among age-matched men and postmenopausal women
[ Mendelsohn and Karas, 1999 ]. Estrogen replacement
therapy for postmenopausal women significantly reduces
the incidence of atherosclerotic diseases [ Mendelsohn
and Karas, 1999 ]. Additionally, estrogen increases
vasodilatation and inhibits the response to vascular injury
[ Mendelsohn and Karas, 1999 ].The vasoprotective
effects of estrogen are attributed to both systemic effects,
such as decreased serum total cholesterol and alteration
of serum lipoproteins, and direct effects on blood vessels
through rapid non-genomic and longer-term genomic
pathways [Mendelsohn and Karas, 1999]. Both the
non-genomic and the genomic cardiovascular effects of
estrogen are mediated by estrogen receptor α (ER α )
and ER β [Bakir et al., 2000; Chen et al., 1999].
ERs are hormone-inducible transcription factors requiring
coactivators to modulate the transcription of their target
genes [ Xu and O'Malley, 2002 ].The steroid receptor
coactivator-3 (SRC-3/p/CIP/RAC3/ AIB1/ACTR/TRAM-1)
belongs to the p160 SRC family that also contains the
other two homologous coactivators, SRC-1 and SRC-2
(TIF2/GRIP-1) [ Xu and O'Malley, 2002 ].These
coactivators interact with ERs and other nuclear receptors
(NRs) in a ligand-dependent manner and strongly
coactivate the transcription of cellular target genes by
NRs.
SRC-3 was recently shown to be associated with ER α
bound to the estrogen responsive promoters of target
genes after estrogen treatment [ Shang et al., 2000 ].The
levels of SRC-3 are also related to the
estrogen-dependent growth of certain breast cancer cells
[ Planas-Silva et al., 2001 ].These findings suggest that
SRC-3 may play an important role in mediating ER
function in vivo.
Coexpression of SRC-3 with ER α and
ER β in vascular smooth muscle cells
(VSMCs) and endothelial cells (ECs)
Previous studies have shown that both ER α and ER β
are expressed in VSMCs and ECs [Karas et al., 1994;
Venkov et al., 1996]. As an initial step to study the role
of SRC-3 in cardiovascular system, we investigated its
expression pattern by using the phenotypically normal
SRC-3
+/- mice harboring a knock-in LacZ reporter that
was regulated by the endogenous SRC-3 promoter [ Xu
et al., 2000 ]. Our results demonstrated that SRC-3 is
highly expressed in both VSMCs and ECs throughout the
entire blood vessel system, but not expressed in the
myocardial cells [ Yuan et al., 2002 ].These findings
indicate that SRC-3 is coexpressed with ERs in both
VSMCs and ECs, suggesting that SRC-3 and ERs may
have a functional partnership in these two cell types.
Faster Neointima Growth in Intact
SRC-3-/- Mice
To investigate the role of SRC-3 in estrogen-facilitated
vascular remodeling after vessel injury, we used a carotid
artery ligation model whereby neointimal formation is
consistently induced after cessation of blood flow [ Kumar
and Lindner, 1997 ].The vasoprotective effect of estrogen
in this model appears to protect the vascular wall from
thickening through inhibiting neointimal formation during
the injury-induced vessel wall remodeling.The basic
experimental steps are illustrated in Figure 1 A. In WT
mice, significant growth of a stenotic neointima was
observed 4 weeks after ligation. Much higher levels of
arterial neointima formation were observed in SRC-3
-/-
mice compared to WT mice ( Figure 1 B, a & b).
Quantitative measurements revealed that the average
intimal area in SRC-3
-/- mice was 2 fold larger than that
in the age-matched WT mice. No differences in medial
wall growth were observed between WT and SRC-3
-/-
mice [ Yuan et al., 2002 ].These observations
demonstrate that disruption of the SRC-3 gene facilitates
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Perspective  Nuclear Receptor Signaling  |  The Open Access Journal of the Nuclear Receptor Signaling AtlasFigure 1 . Cardiovascular phenotype of SRC-3 knockout mice  (A), experimental schedule for animal treatment. (B). (a) and (b), representative
photomicrographs of neointima formation 4 weeks after carotid ligation in intact WT and SRC-3 knockout (KO) mice. (c) – (h), morphology of right
control (c & d) and left ligated (e-h) carotid arteries of ovariectomized WT and SRC-3-/- mice treated with vehicle (c-f) or E2 (g & h) 2 weeks after
ligation.
neointimal growth in the process of injury-induced
vascular remodeling.
The faster growth of neointima in SRC-3
-/- mice was not
due to alteration of ER α or ER β levels since no changes
of their protein levels in the vascular wall could be
detected [ Yuan et al., 2002 ]. Other contributing factors
might involve estrogen and ER functional levels in
SRC-3
-/- mice. Actually, lower serum estrogen levels have
been identified in female SRC-3
-/- mice [ Xu et al., 2000
].Therefore, analyses of neointimal formation were
repeated in ovariectomized WT and SRC-3
-/- mice, in
which estrogen and estrogen-dependent ER function
were largely eliminated. Indeed, the neointima was formed
equally in both ovariectomized WT and SRC-3 
-/- mice (
Figure 1 B, e & f) [ Yuan et al., 2002 ].These results
suggest that the neointimal overgrowth after vascular
injury in the intact SRC-3
-/- mice is likely accredited to the
reduction in estrogen levels and/or ER functions.
Attenuated Inhibition of Neointima
Formation in SRC-3-/- Mice by Estrogen
Next, we compared the degrees of estrogen
(E2)-dependent inhibition of neointimal growth between
ovariectomized and E2-treated WT and SRC-3
-/- mice.
E2 treatment almost completely inhibited the neointima
formation after the carotid ligation in ovariectomized WT
mice ( Figure 1 B, g). In contrast, the parallel treatment
with equal amounts of E2 only partially inhibited the
neointima formation in the age-matched and
ovariectomized SRC-3
-/- mice ( Figure 1 B, h). Statistics
revealed a highly significant difference (p < 0.01) between
the average intimal areas of WT and SRC-3
-/- mice treated
with E2. In addition, minimal changes in medial wall area
were observed in vehicle- or E2-treated WT and SRC-3
-/-
mice. Correlated with the insensitive neointimal inhibition
by E2, the neointima in SRC-3
-/- mice also exhibited a
higher degree of cell proliferation [ Yuan et al., 2002 ]. In
conclusion, the loss of SRC-3 in VSMCs and/or ECs
results in a loss of sensitivity to estrogen-induced
inhibition of neointima formation, probably due to an
impaired suppression of intimal cell proliferation during
vascular remodeling through a direct or indirect
estrogen-regulated pathway.
Conclusion
Our study demonstrates that SRC-3, an ER coactivator,
is expressed in VSMCs and ECs and required for the
estrogen-dependent vasoprotective effect mediated by
ERs. It is clear that removal of SRC-3 only partially
desensitizes the inhibition of neointima formation by
estrogen.This likely is due to the compensation of other
ER coactivators such as SRC-1 and SRC-2 [ Xu and
O'Malley, 2002 ]. Former studies have shown that both
ER α and ER β are responsible for the inhibition of the
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] . ER α is required for estrogen-accelerated
reendothelialization [ Brouchet et al., 2001 ], while ER β
is required for regulation of vasoconstriction and blood
pressure [ Zhu et al., 2002 ]. Since a poor
reendothelialization and a higher vasoconstriction may
contribute to the neointima formation, SRC-3 may serve
as a coactivator for both ERs in the inhibition of intima
formation by estrogen.The clinical trial Heart
Estrogen-Progestin Replacement Study (HERS) was
unable to prove therapeutic effects of estrogen on
pre-existing coronary artery diseases [ Tolbert and Oparil,
2001 ]. Probably, an active estrogen-signaling pathway
is required in the early stages of vascular injury to inhibit
neointima formation as demonstrated in animal models
[ Mori et al., 2000 ]. In addition to the lack of estrogen
and the reduction in ER levels as seen in diseased human
coronary arteries [ Losordo et al., 1994 ], the loss of ER
coactivator functions in the diseased arteries will also
result in the loss of estrogen-induced vasoprotection.
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